Insitro Stock
| Valuation | $2.57B1 |
| Valuation Date | Mar 15, 2021 |
| Implied Valuation | n/a |
| Last Price | $12.09 |
| 52-Week High | $12.94 |
| 52-Week Low | $12.08 |
| YTD Return | -6.28% |
| 1-Year Return | -6.28% |
| 3-Year Return | -10.84% |
| Total Funding | $643M2, 3, 4 |
| Latest Round Amount | $400M2 |
| Latest Round | Series C |
| Funding Rounds | 3 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Insitro
Insitro is an AI therapeutics company that uses machine learning on large-scale human genetics and cellular experiments to find disease targets and design medicines. Its Virtual Human platform combines clinical and cellular data to identify causal drivers of disease. Its TherML engine then designs small molecules, oligonucleotides and biologics against those targets. Insitro makes money by developing its own pipeline in metabolic disease and neuroscience and through discovery collaborations with drugmakers such as AstraZeneca, Bristol Myers Squibb, Eli Lilly and Gilead. It was founded by Daphne Koller, a Stanford computer scientist and co-founder of Coursera.
Invest in Insitro
Insitro is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Clarity (formerly Hiive).
Clarity is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on ClarityStock Analysis may be compensated for user sign-ups through Clarity links. Clarity is not affiliated with Stock Analysis. Securities offered by Clarity Capital Limited, member of FINRA/SIPC.
Related Companies
News
AstraZeneca Strikes Up to $1.5 Billion AI Drug Discovery Deal With Insitro
The drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1.46 billion subject to meeting targets.
insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies
insitro signed a worldwide exclusive research collaboration with AstraZeneca to find targets and drugs for MASH and cardiomyopathies using its Virtual Human platform. The company will receive $40 mill...
insitro Designed Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab
Machine learning models insitro built with Eli Lilly to predict in vitro and in vivo properties of small molecules are now available to certain biotechs through Lilly TuneLab. The models were trained ...
insitro Appoints Hideo Makimura as Chief Medical Officer to Lead Its Transition to a Clinical-Stage Company
insitro named Hideo Makimura chief medical officer as it prepares to take its metabolic disease and neuroscience pipeline into first-in-human trials. Makimura previously led clinical development at Af...
insitro Presents New Data Demonstrating Its AI-Discovered MASH Candidate Shows Anti-Fibrotic Signal Beyond Liver-Fat Reduction at the American Diabetes Association 86th Scientific Sessions
insitro presented preclinical data showing that liver-targeted silencing of IRS1 reduced fibrosis progression and injury biomarkers in a fibrogenic mouse model, with effects that appear partly indepen...
insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets
Bristol Myers Squibb nominated two additional ALS targets discovered on insitro's Virtual Human platform, joining the first target selected in December 2024. insitro received a $10 million milestone a...
insitro Completes First AI-Enabled Human Genetics Study of Brown Adipose Tissue, Shares Differentiated Targets with Anti-Obesity Effects
insitro reported what it calls the first population-scale GWAS of brown adipose tissue, using an AI phenotype from nearly 70,000 UK Biobank MRIs. Knockdown of a prioritized target, BAT-01, cut body we...
insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design
insitro agreed to acquire CombinAbleAI, an Israeli biologics-design startup incubated at AION Labs, and launched its TherML platform for designing small molecules, oligonucleotides and complex biologi...
insitro Validates AI-Enabled POSH Platform in Nature Communications, Bridging Critical Gap in Drug Discovery
Nature Communications published insitro research validating its POSH platform, which combines pooled CRISPR screening, Cell Painting imaging and self-supervised deep learning to map gene function at s...
insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro's ChemML Discovery Platform
insitro and Bristol Myers Squibb extended their ALS collaboration for another year to design molecules against a novel target using insitro's ChemML platform. The extension may provide up to $20 milli...
insitro partners with Lilly to build first-in-kind machine learning models to advance small molecule drug discovery
insitro and Eli Lilly announced a collaboration to build machine learning models that predict pharmacological properties of small molecules, including in vivo behavior, using Lilly's proprietary precl...
AI-focused biotech insitro cuts 22% of staff, citing 'tumultuous market'
insitro said it laid off about 22% of its workforce, or roughly 60 people, leaving a team of about 230. The company said the cuts extend its cash runway into 2027 through preclinical and clinical mile...
insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS
insitro received $25 million from Bristol Myers Squibb after hitting discovery milestones and selecting the first novel ALS target identified by its platform. The 2020 collaboration included a $50 mil...
insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases
insitro and Eli Lilly signed three agreements to advance metabolic disease medicines, including MASLD programs based on insitro-identified targets. insitro has an option to license Lilly's GalNAc deli...
insitro Raises $400 Million in Series C Financing
insitro raised $400 million in a Series C led by CPP Investments, with participation from Andreessen Horowitz, T. Rowe Price, Casdin Capital, BlackRock, ARCH Venture Partners, Temasek and SoftBank. Pr...